PREDNISOLONE TEBUTATE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Corticosteroid that binds to glucocorticoid receptors, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes) and immune cell activity.
| Metabolism | Primarily hepatic via CYP3A4 to inactive metabolites. |
| Excretion | Renal: primarily as metabolites, <20% unchanged; small fecal/biliary contribution. |
| Half-life | Terminal half-life: 2-4 hours (plasma); clinical effects persist longer (18-36 hours) due to prolonged receptor occupancy and transcriptional effects. |
| Protein binding | 70-90% bound primarily to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | 0.6-1.0 L/kg reflecting extensive distribution into tissues. |
| Bioavailability | Oral: 70-100%; intra-articular: 100% locally, with minimal systemic absorption (systemic bioavailability <10%). |
| Onset of Action | Intra-articular: 24-48 hours; oral: 2-6 hours; intravenous: immediate to 2 hours. |
| Duration of Action | Intra-articular: 1-4 weeks depending on joint and dose; oral: 12-36 hours; intravenous: 24-48 hours. |
| Molecular Weight | 480.59 |
20-60 mg intramuscularly or intra-articularly once daily as a single dose or divided every 6-12 hours; dose varies by indication and severity.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required for renal impairment; use with caution in severe renal impairment due to potential fluid retention. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% or use alternative. |
| Pediatric use | 0.5-2 mg/kg/day intramuscularly or intra-articularly as a single dose or divided every 6-12 hours; not to exceed 80 mg/day. |
| Geriatric use | Initiate at lower end of dosing range (10-20 mg/day) due to increased risk of osteoporosis, glucose intolerance, and immunosuppression; monitor closely. |
| 1st trimester | Corticosteroids are associated with increased risk of cleft palate (orofacial clefts) when used during first trimester. Weigh risk vs benefit; use lowest effective dose. |
| 2nd trimester | Use only if clearly needed; may cause fetal growth restriction and adrenal suppression. Monitor fetal growth. |
| 3rd trimester | Prolonged use may lead to neonatal adrenal suppression. Taper if possible before delivery. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Placental transfer | Prednisolone tebutate is a prodrug hydrolyzed to prednisolone. Prednisolone crosses the placenta minimally (~14-25% of maternal concentration) due to placental 11β-HSD2 activity. |
■ FDA Black Box Warning
None.
| Common Effects | immunosuppression |
| Serious Effects |
Systemic fungal infectionsHypersensitivity to prednisolone tebutate or any component
| Precautions | May cause immunosuppression and increase infection risk., Long-term use may lead to adrenal suppression, osteoporosis, and growth retardation in children., Monitor for hyperglycemia, hypertension, and electrolyte disturbances., Avoid abrupt withdrawal after prolonged therapy. |
| Food/Dietary | No significant food interactions. However, avoid excessive grapefruit juice as it may alter corticosteroid metabolism. Maintain a low-sodium diet if prolonged systemic effects are anticipated. |
Loading safety data…
| Breastfeeding |
| Prednisolone tebutate enters breast milk in low concentrations. At maternal doses up to 40 mg/day, infant exposure is minimal and unlikely to cause adverse effects. For higher doses, monitor infant for growth and adrenal suppression. |
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Increased risk of orofacial clefts (odds ratio 1.5–3.0) based on epidemiological studies. Second/third trimester: Risk of fetal adrenal suppression, low birth weight, and preterm delivery with prolonged use. High doses may cause fetal growth restriction. No specific data for prednisolone tebutate; profile extrapolated from prednisolone. |
| Fetal Monitoring | Monitor maternal blood glucose, blood pressure, and signs of infection. Fetal surveillance with serial growth ultrasounds if prolonged therapy. Assess newborn for adrenal insufficiency, hypoglycemia, and respiratory status. |
| Fertility Effects | No direct negative effects on fertility reported. Adrenal suppression from high-dose therapy may disrupt ovulation; effects reversible upon dose reduction or discontinuation. |
| Clinical Pearls | Prednisolone tebutate is a long-acting corticosteroid suspension for intra-articular, intralesional, or soft tissue injection. Do not inject intravenously or into infected joints. Avoid overuse in weight-bearing joints to prevent joint destruction. Use with caution in patients with diabetes as it may raise blood glucose. Onset of action is slower than other soluble steroids due to its crystalline formulation. |
| Patient Advice | Do not stop taking other medications for your condition without consulting your doctor. · Report signs of infection (redness, swelling, warmth) at injection site. · This medication may raise blood sugar; monitor glucose if diabetic. · Avoid strenuous activity on injected joints for 48 hours. · Tell your doctor if you have had recent vaccinations or have an active infection. |